Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 Gaithersburg, Md. – November 4, 2010 – BGI, the largest genomics organization in the world, and OpGen, Inc., a commercial phase genomics company and exclusive provider of Optical Mapping Technology, announced their joint effort to
Researchers From Rush University Medical Center Present Data at IDWeek 2015 GAITHERSBURG, Md. , Oct. 12, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an early-stage commercial molecular testing and bioinformatics company, today announced that new data from a study with its Acuitas ®
DC’s Public Health Agencies, Healthcare Facilities to Examine Occurrence of “Superbugs” in First-of-Its-Kind Evaluation, Supported by the Centers for Disease Control & Prevention GAITHERSBURG, Md. and WASHINGTON , Nov. 18, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc.
Five-Year Agreement Expands on Prior Supply Agreement SOUTH SAN FRANCISCO, Calif. and GAITHERSBURG, Md. , July 13, 2015 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and OpGen, Inc. (NASDAQ:OPGN) today announced an expanded relationship and new agreement that includes collaborating on the
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279 GAITHERSBURG, Md.–(BUSINESS WIRE)–OpGen, Inc., a provider of innovative whole genome DNA analysis solutions, announced today the
Companies to Introduce Human Chromosome Explorer SM Cloud-Based Informatics and Data Management Platform Tokyo and Gaithersburg, Md.—October 19, 2014 — Hitachi High-Technologies Corporation and OpGen, Inc. , a leading genetic analysis company, today announced the introduction of an Early Access
SALT LAKE CITY and GAITHERSBURG, Md. , Oct. 27, 2016 (GLOBE NEWSWIRE) -- A first-of-its-kind study of 900,000 hospital admissions from an integrated health system has yielded insights into shifts in the epidemiology of multi-drug resistant organisms (MDROs) in the community.
Media Contant: Dan Budwick Pure Communications, Inc. (973) 271-6085 OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279 Companies to develop improved microbial analysis and surveillance systems for public health and infectious disease markets CARLSBAD, Calif. and GAITHERSBURG, Md.
Company to preview automated QuickFISH Digital Imager at 26th European Congress of Clinical Microbiology and Infectious Diseases GAITHERSBURG, Md. , April 11, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat
GAITHERSBURG, Md. , July 12, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the New York State Department of Health (NYSDOH) has approved the Acuitas® MDRO Gene Test for use by physicians and healthcare providers in the state. The approval of OpGen’s CLIA laboratory to